Enstilar使用方法(图解)？

It is a drug used for the topical treatment of plaque psoriasis in people 12 years of age and older. It is for topical use only. Its exact mechanism of action in the treatment of plaque psoriasis is currently unknown.

entilar usage steps

1. Wash your hands before applying Enstilar foam, then remove the lid from the can and shake the can before use.

2. Lift the jar at least 1.5 inches away from the affected area.

3. Place the can anywhere except on the side (horizontally) and spray foam. Please press the nozzle when spraying. The size of Enstilar foam will gradually decrease after spraying.

4. Gently rub the affected area with Enstilar foam, and follow the instructions of the medical staff to repeat the above steps to apply Enstilar foam to other designated areas.

5. After using the Enstilar foam, place the lid back on the jar.

6. Wash your hands after using Enstilar Foam, unless you are using hand medication.

enstilar use

1. Do not let entilar foam get close to or enter the mouth, eyes or vagina. If you accidentally get entilar foam on your face, mouth, or eyes, wash the area immediately with water. Do not swallow entilar foam.

2. Do not expose Enstilar foam to temperatures above 120°F (49°C) for heating or storage.

3. Do not puncture or burn the Enstilar foam tank.

4. Do not freeze Enstilar foam.

5. The propellant in Enstilar foam is flammable. Patients should avoid making fire, slapping the skin and smoking during and after medication.

6. Avoid use on the face, groin or armpits, or when skin atrophy occurs in the treatment area.

Enstilar is used once daily for 4 weeks, and the maximum dose should not exceed 60 grams every 4 days. Throw away (dispose of) unused Enstilar foam 6 months after opening.

Enstilar and tolerance

Study Purpose: To evaluate the efficacy and tolerability of Enstilar in psoriasis vulgaris under daily practice conditions.

Research methods: 410 adult patients with psoriasis (56% male) from 87 research sites in Germany participated in a 4-week open-label, prospective, uncontrolled, observational, non-interventional study.

Study Results: At baseline, patients demonstrated mild (41.81%), moderate (49.63%), and severe (8.31%) psoriasis severity, as assessed by the Investigator's Global Assessment (IGA). After 4 weeks of treatment, 49% of patients achieved clear/almost clear IGA. The average patient surface area decreased from 12.91 to 7.55%, and PASI decreased from 10.4 to 5.2. 43% of patients with severe IGA achieved treatment success (IGA = 0/1 and ≥2 steps of improvement), and 93% of patients did not experience any adverse events.

Study Conclusions: Enstilar demonstrated convincing efficacy and tolerability in daily practice, particularly in psoriasis patients with severe disease manifestations.

References:

Gerdes S, Krakor M, Anger T, Hutt HJ, Körber A. Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions. Dermatology. 2017;233(6):425-434. doi: 10.1159/000486700. Epub 2018 Mar 2. PMID: 29502110.

Recommended related articles: